Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel ( Ina-cel) (...
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of...